Table 3.
Changes in serum CPP-1 and CPP-2 over 24 weeks in the SCaRF trial
| Treatment group | Baseline |
Week 12 |
Week 24 |
Within-group treatment effect (95% CI) | P Value | Treatment effect vs. CC (95% CI) | P value | |||
|---|---|---|---|---|---|---|---|---|---|---|
| N | Median (IQR) | N | Median (IQR) | N | Median (IQR) | |||||
| CPP-1, ×105/ml | ||||||||||
| CC | 11 | 26.3 (6.2, 39.1) | 10 | 29.3 (16.3, 35.1) | 10 | 33.9 (20.0, 60.7) | 71.9% (–24.8% to 293%) | 0.20 | — | — |
| SH + SC | 20 | 18.7 (7.2, 41.3) | 17 | 6.4 (3.8, 12.4) | 16 | 9.8 (5.9, 33.9) | –49.7% (–75.8% to 4.3%) | 0.07 | –70.6% (–89.8 to –15.2) | 0.02 |
| CPP-2, ×105/ml | ||||||||||
| CC | 11 | 1.5 (1.0, 3.0) | 10 | 1.3 (0.8, 3.0) | 10 | 1.5 (1.0, 2.2) | 17.4% (–44.8% to 149%) | 0.68 | — | — |
| SH + SC | 20 | 3.2 (0.9, 5.8) | 17 | 1.2 (0.7, 2.7) | 16 | 2.9 (1.5, 5.7) | –56.5% (–84.2% to 20.1%) | 0.11 | –52.2% (–86.7 to 71.35) | 0.26 |
CC, calcium carbonate; CPP, calciprotein particles; IQR, interquartile range; SC, sevelamer carbonate; SCaRF, Sevelamer Versus Calcium to Reduce Fetuin-A-containing Calciprotein Particles in Dialysis; SH, sevelamer hydrochloride; 95% CI, 95% confidence interval.
Serum CPP levels are expressed as median (25th, 75th percentiles) using all available data (N). CPP-1 and CPP-2 values were log-transformed before analysis. Estimated treatment effects are expressed as the percentage change from baseline or relative to CC treatment group (reference category). Mixed-effects analyses are expressed after controlling for the baseline level of the parameter tested.
P values < 0.025 are considered statistically significant owing to multiple comparisons.